ATE488501T1 - Cyclopropylpiperidinglycin-transporter-inhibito - Google Patents

Cyclopropylpiperidinglycin-transporter-inhibito

Info

Publication number: ATE488501T1
Authority: AT; Austria
Prior art keywords: cyclopropylpiperidinglycine; inhibito; transporter; glycine transporter; transporter glyt1
Prior art date: 2004-09-30

Application number

AT05801197T

Other languages

English (en)

Inventor

Craig Lindsley

David Wisnoski

Scott Wolkenberg

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-30

Filing date

2005-09-26

Publication date

2010-12-15

2005-09-26 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2010-12-15 Application granted granted Critical

2010-12-15 Publication of ATE488501T1 publication Critical patent/ATE488501T1/de

Links

102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 2
108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 2
102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 abstract 2
101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 abstract 2
JUBXTBVKELTJEX-UHFFFAOYSA-N 1-cyclopropylpiperidine Chemical class C1CC1N1CCCCC1 JUBXTBVKELTJEX-UHFFFAOYSA-N 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000004064 dysfunction Effects 0.000 abstract 1
230000000926 neurological effect Effects 0.000 abstract 1
208000020016 psychiatric disease Diseases 0.000 abstract 1
230000024587 synaptic transmission, glutamatergic Effects 0.000 abstract 1
230000027682 synaptic transmission, glycinergic Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05801197T 2004-09-30 2005-09-26 Cyclopropylpiperidinglycin-transporter-inhibito ATE488501T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US61494204P	2004-09-30	2004-09-30
PCT/US2005/034301 WO2006039221A2 (en)	2004-09-30	2005-09-26	Cyclopropyl piperidine glycine transporter inhibitors

Publications (1)

Publication Number	Publication Date
ATE488501T1 true ATE488501T1 (de)	2010-12-15

Family

ID=36142986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05801197T ATE488501T1 (de)	2004-09-30	2005-09-26	Cyclopropylpiperidinglycin-transporter-inhibito

Country Status (16)

Country	Link
US (1)	US7776886B2 (de)
EP (1)	EP1797035B1 (de)
JP (1)	JP4646984B2 (de)
KR (1)	KR20070058565A (de)
CN (1)	CN101031547A (de)
AT (1)	ATE488501T1 (de)
AU (1)	AU2005292323B2 (de)
BR (1)	BRPI0515954A (de)
CA (1)	CA2581582C (de)
DE (1)	DE602005024838D1 (de)
IL (1)	IL182253A0 (de)
MX (1)	MX2007003816A (de)
NO (1)	NO20072208L (de)
RU (1)	RU2387644C2 (de)
WO (1)	WO2006039221A2 (de)
ZA (1)	ZA200701612B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070105902A1 (en) *	2003-11-12	2007-05-10	Lindsley Craig W	4-Phenyl piperdine sulfonyl glycine transporter inhibitors
CA2560256C (en) *	2004-03-24	2013-02-19	Merck & Co., Inc.	Heteroaryl piperidine glycine transporter inhibitors
EP1745018A1 (de) *	2004-04-29	2007-01-24	Merck & Co., Inc.	Inhibitoren des azetidinglycintransporters
WO2005107469A2 (en) *	2004-05-05	2005-11-17	Merck & Co., Inc.	Morpholinyl piperidine glycine transporter inhibitors
JP5055493B2 (ja) *	2004-12-21	2012-10-24	メルクシャープエンドドームリミテッド	Ｇｌｙｔ１阻害薬としてのピペリジンおよびアゼチジン誘導体
EP1891002B1 (de) *	2005-06-06	2012-05-30	Merck Sharp & Dohme Limited	Cyclohexansulfonyl-derivate als glyt1-hemmer zur behandlung von schizophrenie
AU2006258842B2 (en)	2005-06-13	2011-09-15	Merck Sharp & Dohme Limited	Therapeutic agents
JP5175736B2 (ja) *	2005-10-28	2013-04-03	メルク・シャープ・エンド・ドーム・コーポレイション	ピペリジングリシン輸送体阻害剤
WO2010102003A2 (en)	2009-03-03	2010-09-10	Vanderbilt University	Alkylsulfonyl-2,3-dihydrospiro[indene-1,4'-piperidine] analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
EP3134406A1 (de)	2014-04-24	2017-03-01	Dart Neuroscience (Cayman) Ltd	Substituierte 2,4,5,6-tetrahydropyrrolo [ 3,4-c ] pyrazol-und 4,5,6,7-tetrahydro-2 h-pyrazolo [ 4,3-c ] pyridinverbindungen als glyt1-inhibitoren
EP3215500A1 (de)	2014-11-05	2017-09-13	Dart NeuroScience (Cayman) Ltd.	Substituierte azetidinylverbindungen als glyt1-inhibitoren

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5532237A (en)	1995-02-15	1996-07-02	Merck Frosst Canada, Inc.	Indole derivatives with affinity for the cannabinoid receptor
US6303637B1 (en) *	1998-10-30	2001-10-16	Merck & Co., Inc.	Heterocyclic potassium channel inhibitors
CN101230034A (zh) *	2000-03-06	2008-07-30	阿卡蒂亚药品公司	用于治疗5-羟色胺相关性疾病的氮杂环化合物
JP2003528088A (ja)	2000-03-23	2003-09-24	メルクエンドカムパニーインコーポレーテッド	メラノコルチン受容体作働薬としての置換ピペリジン類
US7507767B2 (en)	2001-02-08	2009-03-24	Schering Corporation	Cannabinoid receptor ligands
CN101684091A (zh) *	2001-11-14	2010-03-31	先灵公司	类大麻苷受体配体
GB0130696D0 (en) *	2001-12-21	2002-02-06	Smithkline Beecham Plc	Chemical Compounds
TW200403058A (en)	2002-04-19	2004-03-01	Bristol Myers Squibb Co	Heterocyclo inhibitors of potassium channel function
US20070105902A1 (en) *	2003-11-12	2007-05-10	Lindsley Craig W	4-Phenyl piperdine sulfonyl glycine transporter inhibitors
CA2560256C (en) *	2004-03-24	2013-02-19	Merck & Co., Inc.	Heteroaryl piperidine glycine transporter inhibitors
EP1745018A1 (de)	2004-04-29	2007-01-24	Merck & Co., Inc.	Inhibitoren des azetidinglycintransporters
WO2005107469A2 (en)	2004-05-05	2005-11-17	Merck & Co., Inc.	Morpholinyl piperidine glycine transporter inhibitors
JP5055493B2 (ja) *	2004-12-21	2012-10-24	メルクシャープエンドドームリミテッド	Ｇｌｙｔ１阻害薬としてのピペリジンおよびアゼチジン誘導体
EP1891002B1 (de)	2005-06-06	2012-05-30	Merck Sharp & Dohme Limited	Cyclohexansulfonyl-derivate als glyt1-hemmer zur behandlung von schizophrenie
EP1942733B1 (de)	2005-09-29	2012-03-21	Merck Sharp & Dohme Corp.	Radioaktiv markierte glycintransporter-hemmer
JP5175736B2 (ja)	2005-10-28	2013-04-03	メルク・シャープ・エンド・ドーム・コーポレイション	ピペリジングリシン輸送体阻害剤

2005
- 2005-09-26 EP EP05801197A patent/EP1797035B1/de not_active Expired - Lifetime
- 2005-09-26 JP JP2007534679A patent/JP4646984B2/ja not_active Expired - Fee Related
- 2005-09-26 AT AT05801197T patent/ATE488501T1/de not_active IP Right Cessation
- 2005-09-26 DE DE602005024838T patent/DE602005024838D1/de not_active Expired - Lifetime
- 2005-09-26 AU AU2005292323A patent/AU2005292323B2/en not_active Ceased
- 2005-09-26 KR KR1020077007362A patent/KR20070058565A/ko not_active Withdrawn
- 2005-09-26 BR BRPI0515954-7A patent/BRPI0515954A/pt not_active IP Right Cessation
- 2005-09-26 WO PCT/US2005/034301 patent/WO2006039221A2/en not_active Ceased
- 2005-09-26 CA CA2581582A patent/CA2581582C/en not_active Expired - Lifetime
- 2005-09-26 CN CNA2005800331179A patent/CN101031547A/zh active Pending
- 2005-09-26 MX MX2007003816A patent/MX2007003816A/es active IP Right Grant
- 2005-09-26 RU RU2007116165/04A patent/RU2387644C2/ru not_active IP Right Cessation
- 2005-09-26 US US11/664,190 patent/US7776886B2/en active Active
2007
- 2007-02-23 ZA ZA200701612A patent/ZA200701612B/xx unknown
- 2007-03-27 IL IL182253A patent/IL182253A0/en unknown
- 2007-04-27 NO NO20072208A patent/NO20072208L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE602005024838D1 (en)	2010-12-30
EP1797035A4 (de)	2009-08-05
AU2005292323B2 (en)	2011-06-09
US20080108663A1 (en)	2008-05-08
EP1797035A2 (de)	2007-06-20
MX2007003816A (es)	2007-04-24
NO20072208L (no)	2007-04-27
BRPI0515954A (pt)	2008-08-12
JP4646984B2 (ja)	2011-03-09
RU2387644C2 (ru)	2010-04-27
WO2006039221A2 (en)	2006-04-13
CA2581582C (en)	2010-07-20
AU2005292323A1 (en)	2006-04-13
CN101031547A (zh)	2007-09-05
CA2581582A1 (en)	2006-04-13
US7776886B2 (en)	2010-08-17
JP2008514705A (ja)	2008-05-08
IL182253A0 (en)	2007-09-20
EP1797035B1 (de)	2010-11-17
RU2007116165A (ru)	2008-11-10
WO2006039221A3 (en)	2006-09-08
KR20070058565A (ko)	2007-06-08
ZA200701612B (en)	2009-05-27

Legal Events

Date	Code	Title	Description
2011-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
WO2005046601A3 (en)	2005-08-18	4-phenyl piperdine sulfonyl glycine transporter inhibitors
NO20072208L (no)	2007-04-27	Syklopropylpiperidinglysintransportorinhibitorer.
WO2005094514A3 (en)	2006-04-20	Heteroaryl piperidine glycine transporter inhibitors
SG151327A1 (en)	2009-04-30	Deazapurines useful as inhibitors of janus kinases
ATE557021T1 (de)	2012-05-15	Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
EA200900098A1 (ru)	2009-06-30	Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов
ZA200707342B (en)	2009-03-25	Pyrrolopyrimidines useful as inhibitors of protein kinase
DE602007008434D1 (de)	2010-09-23	Rezeptoren
CY1112238T1 (el)	2015-12-09	Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
CR9347A (es)	2007-12-17	Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MA31451B1 (fr)	2010-06-01	Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
WO2005063766A3 (en)	2005-09-09	Bicyclic heterocyclic p-38 kinase inhibitors
EA201170624A1 (ru)	2011-12-30	Изоникотинамидные антагонисты рецепторов орексинов
CY1106902T1 (el)	2012-09-26	Κρυσταλλικη μορφη μηλεϊνικης ασεναπινης
NO20080765L (no)	2005-01-10	Prodrug av eksitasjonsaminosyrer
DE602005023172D1 (de)	2010-10-07	Hydantoinderivate zur behandlung von entzündlichen erkrankungen
TW200800976A (en)	2008-01-01	New compounds for the treatment of neurological, psychiatric or pain disorders
WO2010030891A3 (en)	2010-06-03	Aryl guanidine f1f0-atpase inhibitors and related methods
ATE494890T1 (de)	2011-01-15	Alpha-aminoamid-derivate zur behandlung von suchtstörungen
EA200702109A1 (ru)	2008-06-30	Алкинилпирролопиримидины и их применение в качестве ингибиторов hsp90
EA200700909A1 (ru)	2007-12-28	Азаиндолкарбоксамиды
CY1109992T1 (el)	2014-09-10	Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
EA200801343A1 (ru)	2008-12-30	Иммуноглобулины, направленные против nogo
WO2007053400A3 (en)	2007-09-20	Piperidine glycine transporter inhibitors
TW200724140A (en)	2007-07-01	Hydantoin compounds